A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). (February 2014)

• Record Type: Journal Article
• Authors: Pan, Haitao; Xie, Fang; Liu, Ping; Xia, Jielai; Ji, Yuan
• Is Part Of: Clinical trials. Volume 11:Number 1(2014)
• Page Start: 49
• Page End: 59
• Publication Date: 2014-02
• Subjects: 615.5072405
• DOI: 10.1177/1740774513500081
• Languages: English
• ISSNs: 1740-7745

Abstract

Background: Standard drug development conducts phase I dose finding and phase II dose expansion sequentially and separately. Information between the two phases is rarely shared. Administratively, such a sequential process is time-consuming and burdensome. Purpose: We propose seamless dose escalation/expansion with adaptive randomization scheme (SEARS), a seamless design that combines phase I dose escalation based on toxicity with phase II dose expansion and dose comparison based on efficacy. SEARS allows extension from phase I to phase II under one design with no gap in between and employs a dynamic and parallel procedure involving simultaneous dose escalation, dose graduation, and adaptive randomization. Methods: SEARS integrates three components into a seamless scheme. Specifically, in phase I, SEARS applies the modified toxicity probability interval (mTPI) method to monitor dose escalation based on toxicity outcome. Doses that show promising efficacy and safety are immediately graduated from phase I and placed to a phase II stage in which patients are adaptively randomized based on efficacy outcome. Phase I dose escalation, dose graduation, and phase II adaptive randomization proceed simultaneously throughout the entire trial. Results: Examples are given comparing SEARS with two other designs, in which superior performance of SEARS is demonstrated. An important and promising finding is that SEARS reduces sample sizes without losing power. R program and demo slides of SEARS can be obtained athttp://health.bsd.uchicago.edu/yji/soft.html Limitation: We assume that the binary efficacy and toxicity response can be measured in the same time frame. This is often achievable with surrogate efficacy markers in practice.